RGLS5040

Regulus reports a trio of pipeline setbacks
BioPharma Dive
Tue, 06/13/17 - 12:00 pm
Regulus
RG-101
RGLS5040
RG-105
cholestatic disease
type 2 diabetes
hepatitis C